A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid TumorsPhilippe L. Bédard, Cristiana Sessa, Josep Tabernero et al.|Clinical Cancer Research|2014Cited by 326
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trialJosé Manuel Pérez-García, Sofía Braga, Laia Garrigós et al.|Neuro-Oncology|2022Cited by 247
Enhancing global access to cancer medicinesJavier Cortés, Joaquı́n Arribas, José Manuel Pérez-García et al.|CA A Cancer Journal for Clinicians|2020Cited by 205